STOCK TITAN
  1. Home
  2. Sec-filings
  3. FLGT
  4. [Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 1,201 shares of common stock on May 27, 2026 at a weighted-average price of $17.60 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024.

Following the sale, Xie directly holds 369,751 shares of Fulgent Genetics common stock. An additional 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, where Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Xie Jian
Role President and COO
Sold 1,201 shs ($21K)
Type Security Shares Price Value
Sale Common Stock 1,201 $17.60 $21K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 369,751 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)
Footnotes (3)
  1. F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
  2. F2. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. F3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Shares sold 1,201 shares Open-market sale on May 27, 2026
Weighted-average sale price $17.60 per share Common stock sale on May 27, 2026
Sale price range $17.39–$17.76 per share Multiple transactions in the reported sale
Direct holdings after sale 369,751 shares Common stock directly owned following transaction
Indirect trust holdings 220,816 shares Held by The Hsieh Family Dynasty Trust
Net shares sold 1,201 shares Net buy/sell direction in transaction summary
restricted stock units financial
"tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted-average sale price financial
"multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price."
tax withholding obligations financial
"sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units"
pecuniary interest financial
"Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein."
indirect ownership financial
"Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did Fulgent Genetics (FLGT) report for Jian Xie?
Fulgent Genetics reported that President and COO Jian Xie sold 1,201 shares of common stock. The open-market sale occurred on May 27, 2026 and was disclosed on Form 4, detailing the transaction size, price, and post-transaction holdings.

At what price did Jian Xie sell Fulgent Genetics (FLGT) shares?
Jian Xie sold 1,201 Fulgent Genetics shares at a weighted-average price of $17.60 per share. The shares were sold in multiple trades, with individual prices ranging from $17.39 to $17.76, as disclosed in the Form 4 filing footnotes.

Why did Jian Xie sell 1,201 Fulgent Genetics (FLGT) shares?
The 1,201 shares were sold to cover tax withholding obligations tied to vesting restricted stock units. These RSUs were granted to Jian Xie on February 26, 2024, and the sale reflects a tax-related transaction rather than a discretionary portfolio change.

How many Fulgent Genetics (FLGT) shares does Jian Xie hold after the sale?
After the reported sale, Jian Xie directly holds 369,751 Fulgent Genetics common shares. Separately, 220,816 shares are held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and has only pecuniary interest.

What is The Hsieh Family Dynasty Trust’s role in Fulgent Genetics (FLGT) holdings?
The Hsieh Family Dynasty Trust holds 220,816 Fulgent Genetics shares. Jian Xie serves on the Trust’s investment committee and disclaims beneficial ownership of these shares, except for any pecuniary interest, meaning economic benefit he may receive from them.

Were Jian Xie’s Fulgent Genetics (FLGT) sales executed in a single trade?
No. The Form 4 notes that Jian Xie’s 1,201-share sale occurred through multiple transactions. These trades were executed at prices between $17.39 and $17.76, with the reported $17.60 figure representing the weighted-average sale price across all trades.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Xie Jian
(Last)(First)(Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE
(Street)
EL MONTE CALIFORNIA 91731
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026S1,201(1)D$17.6(2)369,751D
Common Stock220,816IBy Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
2. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
/s/ Paul Kim as Attorney-in-Fact05/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR